Methazolamide

Methazolamide

Clinical data
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Oral
ATC code	S01EC05 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	55%
Elimination half-life	14 hours
Identifiers
IUPAC name N-(3-methyl-5-sulfamoyl-3H- 1,3,4-thiadiazol-2-ylidene) ethanamide
CAS Number	554-57-4
PubChem CID	4100
DrugBank	APRD00740
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C5H8N4O3S2
Molar mass	236.274 g/mol

WikiDoc Resources for Methazolamide
Articles
Most recent articles on Methazolamide Most cited articles on Methazolamide Review articles on Methazolamide Articles on Methazolamide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Methazolamide Images of Methazolamide Photos of Methazolamide Podcasts & MP3s on Methazolamide Videos on Methazolamide
Evidence Based Medicine
Cochrane Collaboration on Methazolamide Bandolier on Methazolamide TRIP on Methazolamide
Clinical Trials
Ongoing Trials on Methazolamide at Clinical Trials.gov Trial results on Methazolamide Clinical Trials on Methazolamide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Methazolamide NICE Guidance on Methazolamide NHS PRODIGY Guidance FDA on Methazolamide CDC on Methazolamide
Books
Books on Methazolamide
News
Methazolamide in the news Be alerted to news on Methazolamide News trends on Methazolamide
Commentary
Blogs on Methazolamide
Definitions
Definitions of Methazolamide
Patient Resources / Community
Patient resources on Methazolamide Discussion groups on Methazolamide Patient Handouts on Methazolamide Directions to Hospitals Treating Methazolamide Risk calculators and risk factors for Methazolamide
Healthcare Provider Resources
Symptoms of Methazolamide Causes & Risk Factors for Methazolamide Diagnostic studies for Methazolamide Treatment of Methazolamide
Continuing Medical Education (CME)
CME Programs on Methazolamide
International
Methazolamide en Espanol Methazolamide en Francais
Business
Methazolamide in the Marketplace Patents on Methazolamide
Experimental / Informatics
List of terms related to Methazolamide

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Methazolamide (Neptazane®) is a carbonic anhydrase inhibitor.

References

• Iyer G, Bellantone R, Taft D (1999). "In vitro characterization of the erythrocyte distribution of methazolamide: a model of erythrocyte transport and binding kinetics". J Pharmacokinet Biopharm. 27 (1): 45–66. PMID 10533697.CS1 maint: Multiple names: authors list (link)
• RxList. "Neptazane".
• Shirato S, Kagaya F, Suzuki Y, Joukou S (1997). "Stevens-Johnson syndrome induced by methazolamide treatment". Arch Ophthalmol. 115 (4): 550–3. PMID 9109770.CS1 maint: Multiple names: authors list (link)
• Skorobohach B, Ward D, Hendrix D (2003). "Effects of oral administration of methazolamide on intraocular pressure and aqueous humor flow rate in clinically normal dogs". Am J Vet Res. 64 (2): 183–7. PMID 12602587.CS1 maint: Multiple names: authors list (link)